Raymond James Financial
COGT icon

Raymond James Financial’s Cogent Biosciences COGT Stock Holding History

Raymond James Financial’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.2M Sell
369,715
-6,204
-2% -$229K ﹤0.01% 1732
2025
Q4 		$13.4M Buy
375,919
+86,522
+30% +$2.43M ﹤0.01% 1740
2025
Q3 		$4.16M Buy
289,397
+289,352
+643,004% +$3.43M ﹤0.01% 2595
2025
Q2 		$323 Buy
+45
New +$249 ﹤0.01% 6731

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Raymond James Financial's COGT Position: Q1 2026 in Review

Raymond James Financial reduced its Cogent Biosciences (COGT) stake by 1.7% in Q1 2026, selling an estimated $229K and leaving 369,715 shares worth $14.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1732.

Raymond James Financial first reported a position in COGT in Q2 2025 and has held it in 4 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Raymond James Financial held 369,715 shares of Cogent Biosciences worth $14.2M as of Q1 2026.
  • Raymond James Financial sold 6,204 Cogent Biosciences shares in Q1 2026, an estimated $229K.
  • Cogent Biosciences made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #1732 holding.
  • Raymond James Financial first reported a position in Cogent Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.